Literature: Neuroendocrine Tumours
van der Zwan WA, Bodei L, Mueller-Brand J, de Herder W, Kvols L, Kwekkeboom D.
GEP-NETS update: Radionuclide therapy in neuroendocrine tumors.
Eur J Endocrinol. 2014 Aug 12.
Sabet A, Khalaf F, Mahjoob S, Al-Zreiqat A, Biersack HJ, Ezziddin S.
May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):80-8. eCollection 2013.
Wyszomirska A.
Iodine-131 for therapy of thyroid diseases. Physical and biological basis.
Nucl Med Rev Cent East Eur. 2012 Aug 28;15(2):120-3.
Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
J Nucl Med. 2012 Jul;53(7):1155-63.
Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M.
Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.
J Oncol. 2012;2012:872713.
Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C.
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
Horm Metab Res. 2012 May;44(5):390-9.
Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51.
Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ.
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
J Nucl Med. 2011 Sep;52(9):1361-8.
Andersen KF, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, Christensen NJ, Hendel HW.
Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
Cancer Treat Rev. 2011 Apr;37(2):111-9. doi: 10.1016/j.ctrv.2010.07.002. Epub 2010 Aug 2.
Gurgul E, Sowinski J.
Primary hyperthyroidism--diagnosis and treatment. Indications and contraindications for radioiodine therapy.
Nucl Med Rev Cent East Eur. 2011;14(1):29-32.
Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H.
Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma.
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1279-90.
Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA.
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
J Clin Oncol. 2010 Apr 1;28(10):1652-9.
Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N, Babich JW.
Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Cancer Biother Radiopharm. 2009 Aug;24(4):469-75.
Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, Teunissen JJ, de Jong M, van Lom K, de Herder WW, Kwekkeboom DJ.
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)] octreotate.
Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46.
Kizu H, Takayama T, Tsushima H, Noguchi A, Nakajima K, Onoguchi M, Kinuya S.
Localization of metastases from malignant pheochromocytoma in patients undergoing 131I-MIBG therapy with manually fused 123I-MIBG SPECT and CT images.
J Nucl Med Technol. 2008 Dec;36(4):186-8.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP.
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
J Clin Oncol. 2008 May 1;26(13):2124-30.
Gedik GK, Hoefnagel CA, Bais E, Olmos RA.
131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):725-33.
van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T.
Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.
Cancer. 2003 Jul 15;98(2):389-96.
De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
Semin Nucl Med. 2002 Apr;32(2):133-40.
Hoefnagel CA, den Hartog Jager FC, Taal BG, Abeling NG, Engelsman EE.
The role of I-131-MIBG in the diagnosis and therapy of carcinoids.
Eur J Nucl Med. 1987;13(4):187-91.